Brief: Janone Begins Production Of JAN101 cGMP Batch For Phase 2B PAD Trial & Potential COVID-19 Study
Sept 24 (Reuters) - Janone Inc JAN.O :
* JANONE SUCCESSFULLY BEGINS PRODUCTION OF JAN101 CGMP BATCH
FOR
PHASE 2B PERIPHERAL ARTERY DISEASE (PAD) TRIAL AND POTENTIAL
COVID-19 STUDY
* JANONE INC - INITIAL PRODUCTION BATCH WILL BE 250,000
SUSTAINED
RELEASE TABLETS AND MATCHING PLACEBOS
* JANONE INC - PHASE 2B TRIALS TO TREAT PERIPHERAL ARTERY
DISEASE
IS EXPECTED TO BEGIN IN EARLY 2021
Source text for Eikon: ID:nPnbM2Tzka
Further company coverage: JAN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AI Financial
See all newsBrief: ALT5 Sigma Corporation Restores Compliance With Nasdaq Periodic Filing Requirements
Brief: Alt5 Sigma Expects To File Its Quarterly Report On Form 10-Q
Media: Trump-linked crypto venture Alt5 Sigma retains auditor - FT
Brief: ALT5 Sigma Corporation Provides Corporate Update
American Bitcoin steadies after share lock-up expiry sparks near 40% plunge (updated)